Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Royalty Pharma Plc Cl A (NQ: RPRX ) 25.71 +0.04 (+0.16%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Press Releases about Royalty Pharma Plc Cl A < Previous 1 2 Next > Royalty Pharma to Present at the Goldman Sachs 45th Annual Global Healthcare Conference June 04, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Announces Pricing of $1.5 Billion of Senior Unsecured Notes June 03, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma and Agios Pharmaceuticals Enter Into Vorasidenib Royalty Agreement for $905 Million May 28, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma and Cytokinetics Announce Expanded Strategic Funding Collaboration Totaling Up to $575 Million to Support Commercial Launch of Aficamten and to Advance R&D Pipeline May 22, 2024 From Royalty Pharma plc; Cytokinetics Via GlobeNewswire Royalty Pharma to Present at Upcoming Investor Conferences May 13, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Reports First Quarter 2024 Results May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab May 09, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024 April 19, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Second Quarter 2024 Dividend April 17, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference February 28, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Reports Q4 and Full Year 2023 Results February 15, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024 January 30, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Announces Dividend Increase January 19, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference January 08, 2024 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference November 27, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program November 13, 2023 From Royalty Pharma plc Via GlobeNewswire Teva and Royalty Pharma Collaborate to Further Accelerate Olanzapine LAI Program November 13, 2023 From Teva Pharmaceutical Industries Limited Via Business Wire Royalty Pharma Reports Third Quarter 2023 Results November 08, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi October 19, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Fourth Quarter 2023 Dividend October 16, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma To Announce Third Quarter 2023 Financial Results On November 8, 2023 October 11, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Appoints Eric Schneider as Chief Technology Officer September 21, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement September 05, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Present at Upcoming Investor Conferences September 05, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma and Ferring Pharmaceuticals Enter Into US $500 Million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (Nadofaragene Firadenovec-Vncg) August 24, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma and Ferring Pharmaceuticals Enter into US $500 million Royalty Agreement for New Intravesical Gene Therapy Adstiladrin® (nadofaragene firadenovec-vncg) August 24, 2023 From Ferring Pharmaceuticals Via Business Wire Royalty Pharma Reports Second Quarter 2023 Results August 08, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Announce Second Quarter 2023 Financial Results on August 8, 2023 July 18, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma Declares Third Quarter 2023 Dividend July 17, 2023 From Royalty Pharma plc Via GlobeNewswire Royalty Pharma to Present at the Goldman Sachs 44th Annual Global Healthcare Conference June 07, 2023 From Royalty Pharma plc Via GlobeNewswire < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.